Cargando…
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
PURPOSE: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. MATERIALS AND METHODS: From August 2016 to October 2020, we enrolled advanced lun...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016311/ https://www.ncbi.nlm.nih.gov/pubmed/34352999 http://dx.doi.org/10.4143/crt.2021.671 |
_version_ | 1784688503858135040 |
---|---|
author | Huang, Yen-Hsiang Hsu, Kuo-Hsuan Chin, Chun-Shih Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J.W. Chang, Gee-Chen |
author_facet | Huang, Yen-Hsiang Hsu, Kuo-Hsuan Chin, Chun-Shih Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J.W. Chang, Gee-Chen |
author_sort | Huang, Yen-Hsiang |
collection | PubMed |
description | PURPOSE: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. MATERIALS AND METHODS: From August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis. RESULTS: A total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481). CONCLUSION: Our research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients. |
format | Online Article Text |
id | pubmed-9016311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-90163112022-04-27 The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma Huang, Yen-Hsiang Hsu, Kuo-Hsuan Chin, Chun-Shih Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J.W. Chang, Gee-Chen Cancer Res Treat Original Article PURPOSE: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. MATERIALS AND METHODS: From August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis. RESULTS: A total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481). CONCLUSION: Our research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients. Korean Cancer Association 2022-04 2021-08-02 /pmc/articles/PMC9016311/ /pubmed/34352999 http://dx.doi.org/10.4143/crt.2021.671 Text en Copyright © 2022 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Huang, Yen-Hsiang Hsu, Kuo-Hsuan Chin, Chun-Shih Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J.W. Chang, Gee-Chen The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title_full | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title_fullStr | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title_full_unstemmed | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title_short | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma |
title_sort | clinical outcomes of different first-line egfr-tkis plus bevacizumab in advanced egfr-mutant lung adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016311/ https://www.ncbi.nlm.nih.gov/pubmed/34352999 http://dx.doi.org/10.4143/crt.2021.671 |
work_keys_str_mv | AT huangyenhsiang theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT hsukuohsuan theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chinchunshih theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT tsengjengsen theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT yangtsungying theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chenkunchieh theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT sukangyi theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT yusungliang theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chenjeremyjw theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT changgeechen theclinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT huangyenhsiang clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT hsukuohsuan clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chinchunshih clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT tsengjengsen clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT yangtsungying clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chenkunchieh clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT sukangyi clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT yusungliang clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT chenjeremyjw clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma AT changgeechen clinicaloutcomesofdifferentfirstlineegfrtkisplusbevacizumabinadvancedegfrmutantlungadenocarcinoma |